Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio
Mandate

Vinge advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio

February 03, 2011

Vinge has advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio for approximately SEK 2.2 billion. The portfolio consists of 57 properties spread over 42 locations in Sweden. Almost 80 per cent of the rental income emanates from public authorities. Several of the properties have a market value of between SEK 5-40 million, although the portfolio also includes large properties such as the premises occupied by the Swedish Migration Board in Norrköping (Presidenten 1), the municipal council building in Haninge (Söderbymalm 3:486) and Sollentuna police station (Transporten 2). The portfolio comprises a total of 300,000 sq. m. and most of the lettable area consists of office space.

Vinge’s team consisted of partner Patrick Forslund and associates Niclas Winnberg and Daniel Unger.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025